150 related articles for article (PubMed ID: 37397388)
21. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
Kundu K; Cardnell RJ; Zhang B; Shen L; Stewart CA; Ramkumar K; Cargill KR; Wang J; Gay CM; Byers LA
Transl Lung Cancer Res; 2021 Nov; 10(11):4095-4105. PubMed ID: 35004241
[TBL] [Abstract][Full Text] [Related]
22. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
[TBL] [Abstract][Full Text] [Related]
23. Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
Dumoulin DW; Cantini L; Cornelissen R; Vink M; Klaase L; Slooff K; Tebayna N; Mankor JM; Baart SJ; Hendriks R; Dingemans AC; Willemsen M; Aerts JGJV
Eur J Cancer; 2022 Sep; 172():357-366. PubMed ID: 35834843
[TBL] [Abstract][Full Text] [Related]
24. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
[TBL] [Abstract][Full Text] [Related]
25. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Shinn LT; Vo KA; Reeves DJ
Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Calvo E; Sessa C; Harada G; de Miguel M; Kahatt C; Luepke-Estefan XE; Siguero M; Fernandez-Teruel C; Cullell-Young M; Stathis A; Drilon A
Invest New Drugs; 2022 Dec; 40(6):1263-1273. PubMed ID: 35947247
[TBL] [Abstract][Full Text] [Related]
27. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
[TBL] [Abstract][Full Text] [Related]
28. ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW; Zhang Y; Elmeskini R; Zimmermann A; Fu H; Murai Y; Wangsa D; Kumar S; Takahashi N; Atkinson D; Saha LK; Lee CF; Elenbaas B; Desai P; Sebastian R; Sharma AK; Abel M; Schroeder B; Krishnamurthy M; Kumar R; Roper N; Aladjem M; Zenke FT; Ohler ZW; Pommier Y; Thomas A
EMBO Mol Med; 2023 Aug; 15(8):e17313. PubMed ID: 37491889
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer.
Awada AH; Boni V; Moreno V; Aftimos P; Kahatt C; Luepke-Estefan XE; Siguero M; Fernandez-Teruel C; Cullell-Young M; Tabernero J
ESMO Open; 2022 Dec; 7(6):100651. PubMed ID: 36455505
[TBL] [Abstract][Full Text] [Related]
30. Review of real-world experience with lurbinectedin in relapsed/refractory small cell lung cancer.
Wasifuddin M; Ilerhunmwuwa NP; Becerra H; Hakobyan N; Wasifuddin S; Asadi HA; Wang JC
J Chemother; 2024 Jan; ():1-6. PubMed ID: 38234179
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
[TBL] [Abstract][Full Text] [Related]
32. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
[TBL] [Abstract][Full Text] [Related]
33. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Mark M; Rusakiewicz S; Früh M; Hayoz S; Grosso F; Pless M; Zucali P; Ceresoli GL; Maconi A; Schneider M; Froesch P; Tarussio D; Benedetti F; Dagher J; Kandalaft L; von Moos R; Tissot-Renaud S; Schmid S; Metaxas Y
ESMO Open; 2022 Jun; 7(3):100446. PubMed ID: 35427834
[TBL] [Abstract][Full Text] [Related]
34. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
35. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
37. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.
Longo-Muñoz F; Castellano D; Alexandre J; Chawla SP; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Moreno V; Sanz-García E; Awada A; Santaballa A; Subbiah V
Eur J Cancer; 2022 Sep; 172():340-348. PubMed ID: 35830841
[TBL] [Abstract][Full Text] [Related]
38. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Das M; Padda SK; Weiss J; Owonikoko TK
Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS; Khan SR; Singh P; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
[TBL] [Abstract][Full Text] [Related]
40. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]